IMCR
Immunocore Holdings plc
Price Chart
Latest Quote
$31.41
+1.42 (+4.72%)
Current Price
| Previous Close | $29.99 |
| Open | $30.00 |
| Day High | $31.57 |
| Day Low | $29.75 |
| Volume | 339,420 |
Stock Information
| Shares Outstanding | 50.87M |
| Total Debt | $435.68M |
| Cash Equivalents | $844.90M |
| Revenue | $412.81M |
| Net Income | $-27.57M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.60B |
| EPS (TTM) | $-0.56 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.12B |
| Sales | $412.81M |
| Income | $-27.57M |
| Book/sh | $7.75 |
| Cash/sh | $16.61 |
| Employees | 524 |
Financial Ratios
| Quick Ratio | 3.86 |
| Current Ratio | 4.18 |
| Debt/Eq | 110.67 |
| EPS Growth TTM | 158.20% |
Returns & Margins
| ROA | -0.88% |
| ROE | -7.14% |
| Gross Margin | 32.28% |
| Operating Margin | 6.82% |
| Profit Margin | -6.68% |
Ownership
| Insider Ownership | 0.07% |
| Institutional Ownership | 104.57% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -46.74 |
| P/S | 3.87 |
| P/B | 4.05 |
Analyst Data
| Recommendation | none |
| Target Price | $63.49 |
Technical Indicators
| SMA20 | $28.90 |
| SMA50 | $29.18 |
| SMA200 | $32.64 |
| RSI | 67.16 |
| ATR | 1.1821 |
| Shares Float | 42.46M |
| Short Float | 19.14% |
| Short Ratio | 24.37 |
| Volatility | 0.75 |
| Rel Volume | 0.61 |
Performance History
| Week | +10.00% |
| Month | +6.78% |
| Quarter | +3.72% |
| 6 Months | -12.72% |
| YTD | -7.03% |
| Year | -1.89% |
| 3 Years | -48.14% |
| 5 Years | -16.70% |
| 10 Years | -27.30% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $31.41 | 339,420 |
| 2026-06-24 | $29.99 | 1,616,200 |
| 2026-06-23 | $29.20 | 623,500 |
| 2026-06-22 | $29.35 | 893,100 |
| 2026-06-18 | $28.60 | 812,300 |
| 2026-06-17 | $28.55 | 683,100 |
| 2026-06-16 | $28.17 | 254,300 |
| 2026-06-15 | $28.63 | 237,200 |
| 2026-06-12 | $28.96 | 276,800 |
| 2026-06-11 | $28.62 | 412,700 |
| 2026-06-10 | $27.90 | 318,100 |
| 2026-06-09 | $28.52 | 319,600 |
| 2026-06-08 | $27.79 | 454,200 |
| 2026-06-05 | $28.29 | 282,100 |
| 2026-06-04 | $28.76 | 300,600 |
| 2026-06-03 | $28.65 | 648,600 |
| 2026-06-02 | $29.56 | 599,800 |
| 2026-06-01 | $29.13 | 873,900 |
| 2026-05-29 | $28.89 | 505,200 |
| 2026-05-28 | $28.97 | 654,600 |
| 2026-05-27 | $28.52 | 521,200 |
| 2026-05-26 | $29.41 | 385,600 |
About Immunocore Holdings plc
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase 3 clinical trial for the treatment of first-line advanced cutaneous melanoma and in Phase 1/2 clinical trial for the treatment of various tumor types; IMC-R117C which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, such as colorectal cancer; and IMC-P115C which is in Phase 1 clinical trial for patients with tumors that express PRAME. In addition, the company is involved in the development of IMC-M113V which is in Phase 1 clinical trial for a potential functional cure of human immunodeficiency virus; and IMC-I109V which is in Phase 1 clinical trial for a potential functional cure of hepatitis B virus. Further, it develops IMC-S118AI which is in pre-investigation stage for the treatment of type 1 diabetes; and IMC-U120AI which is in pre-investigation stage for the treatment of atopic dermatitis. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
đ° Latest News
Reasons Why Investors Should Consider Betting on Indivior Stock
Zacks âĸ 2026-06-25T13:27:00Z
RVMD Starts Treatment in Phase III Pancreatic Cancer Study on Zoldonrasib
Zacks âĸ 2026-06-24T14:13:00Z
GALT Jumps 11% on FDA Alignment for Belapectin Phase III Path in MASH
Zacks âĸ 2026-06-24T14:05:00Z
EU Clears SNY's Cenrifki for Secondary Progressive Multiple Sclerosis
Zacks âĸ 2026-06-23T15:24:00Z
Xenon Pharmaceuticals Stock Gains 22% in Six Months: Here's Why
Zacks âĸ 2026-06-23T14:59:00Z
Definium Stock Soars 50% as Phase III Depression Study Meets Key Goals
Zacks âĸ 2026-06-23T14:52:00Z
Regenxbio Shares Rise on Plans to Resubmit Navsunli BLA for MPS II
Zacks âĸ 2026-06-23T14:46:00Z
QURE Announces Initial Data on Gene therapy for Temporal Lobe Epilepsy
Zacks âĸ 2026-06-22T14:29:00Z
Is Immunocore Holdings (IMCR) One of the Best Small Cap Stocks to Buy for the Long Term?
Insider Monkey âĸ 2026-06-22T12:10:47Z
QURE Soars as FDA Backs AMT-130 Data for Accelerated Approval
Zacks âĸ 2026-06-19T18:19:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $5,087,000 | $2,731,000 | $1,037,000 | $1,089,000 |
| Cost Of Revenue | $5,087,000 | $2,731,000 | $1,037,000 | $1,089,000 |
| Total Revenue | $400,016,000 | $310,202,000 | $249,428,000 | $174,361,000 |
| Operating Revenue | $400,016,000 | $310,202,000 | $249,428,000 | $174,361,000 |
| Expenses | ||||
| Interest Expense | $12,166,000 | $18,844,000 | $5,154,000 | $5,409,000 |
| Total Expenses | $445,369,000 | $380,663,000 | $309,077,000 | $226,069,000 |
| Other Income Expense | $21,943,000 | $10,750,000 | $-14,073,000 | $12,478,000 |
| Other Non Operating Income Expenses | $19,728,000 | $14,198,000 | $-897,000 | $-1,679,000 |
| Net Non Operating Interest Income Expense | $4,310,000 | $6,774,000 | $12,832,000 | $-1,653,000 |
| Interest Expense Non Operating | $12,166,000 | $18,844,000 | $5,154,000 | $5,409,000 |
| Operating Expense | $440,282,000 | $377,932,000 | $308,040,000 | $224,980,000 |
| Total Other Finance Cost | - | - | - | $1,685,808 |
| Other Operating Expenses | - | - | - | - |
| General And Administrative Expense | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-35,514,000 | $-51,087,000 | $-55,287,000 | $-52,543,000 |
| Net Interest Income | $4,310,000 | $6,774,000 | $12,832,000 | $-1,653,000 |
| Interest Income | $16,476,000 | $25,618,000 | $17,986,000 | $3,756,000 |
| Normalized Income | $-37,263,850 | $-47,763,128 | $-43,323,192 | $-62,665,255 |
| Net Income From Continuing And Discontinued Operation | $-35,514,000 | $-51,087,000 | $-55,287,000 | $-52,543,000 |
| Total Operating Income As Reported | $-45,353,000 | $-70,461,000 | $-59,649,000 | $-51,708,000 |
| Net Income Common Stockholders | $-35,514,000 | $-51,087,000 | $-55,287,000 | $-52,543,000 |
| Net Income | $-35,514,000 | $-51,087,000 | $-55,287,000 | $-52,543,000 |
| Net Income Including Noncontrolling Interests | $-35,514,000 | $-51,087,000 | $-55,287,000 | $-52,543,000 |
| Net Income Continuous Operations | $-35,514,000 | $-51,087,000 | $-55,287,000 | $-52,543,000 |
| Pretax Income | $-19,100,000 | $-52,937,000 | $-60,890,000 | $-40,883,000 |
| Interest Income Non Operating | $16,476,000 | $25,618,000 | $17,986,000 | $3,756,000 |
| Operating Income | $-45,353,000 | $-70,461,000 | $-59,649,000 | $-51,708,000 |
| Gross Profit | $394,929,000 | $307,471,000 | $248,391,000 | $173,272,000 |
| Special Income Charges | - | - | - | $3,631 |
| Per Share | ||||
| Diluted EPS | $-0.71 | $-1.02 | $-1.13 | $-1.09 |
| Basic EPS | $-0.71 | $-1.02 | $-1.13 | $-1.09 |
| Other | ||||
| Tax Effect Of Unusual Items | $465,150 | $-124,128 | $-1,212,192 | $4,034,745 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-5,883,000 | $-26,441,000 | $-38,470,000 | $-44,296,000 |
| Total Unusual Items | $2,215,000 | $-3,448,000 | $-13,176,000 | $14,157,000 |
| Total Unusual Items Excluding Goodwill | $2,215,000 | $-3,448,000 | $-13,176,000 | $14,157,000 |
| Reconciled Depreciation | $3,266,000 | $4,204,000 | $4,090,000 | $5,335,000 |
| EBITDA (Bullshit earnings) | $-3,668,000 | $-29,889,000 | $-51,646,000 | $-30,139,000 |
| EBIT | $-6,934,000 | $-34,093,000 | $-55,736,000 | $-35,474,000 |
| Diluted Average Shares | $50,345,666 | $49,991,064 | $48,888,975 | $45,804,444 |
| Basic Average Shares | $50,345,666 | $49,991,064 | $48,888,975 | $45,804,444 |
| Diluted NI Availto Com Stockholders | $-35,514,000 | $-51,087,000 | $-55,287,000 | $-52,543,000 |
| Tax Provision | $16,414,000 | $-1,850,000 | $-5,603,000 | $11,660,000 |
| Gain On Sale Of Security | $2,215,000 | $-3,448,000 | $-13,176,000 | $14,157,000 |
| Research And Development | $274,869,000 | $222,151,000 | $163,545,000 | $101,921,000 |
| Selling General And Administration | $165,413,000 | $155,781,000 | $144,495,000 | $123,059,000 |
| Gain On Sale Of Ppe | - | - | - | $3,631 |
| Other Gand A | - | - | - | - |
Fetched: 2026-06-14
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $381,033,000 | $360,716,000 | $368,843,000 | $338,903,000 |
| Total Assets | $1,067,269,000 | $1,009,506,000 | $597,001,000 | $526,762,000 |
| Total Non Current Assets | $70,527,000 | $79,642,000 | $68,181,000 | $52,785,000 |
| Other Non Current Assets | $20,282,000 | $17,117,000 | $14,473,000 | $8,887,000 |
| Non Current Deferred Assets | $0 | $14,790,000 | $10,973,000 | $5,121,000 |
| Non Current Deferred Taxes Assets | $0 | $14,790,000 | $10,973,000 | $5,121,000 |
| Current Assets | $996,742,000 | $929,864,000 | $528,820,000 | $473,977,000 |
| Other Current Assets | $6,751,000 | $7,898,000 | $9,711,000 | $3,621,000 |
| Prepaid Assets | $17,975,000 | $13,048,000 | $10,547,000 | $10,109,000 |
| Inventory | $6,742,000 | $5,446,000 | $4,501,000 | $692,000 |
| Receivables | $101,121,000 | $83,096,000 | $61,435,000 | $57,083,000 |
| Taxes Receivable | $27,144,000 | $20,087,000 | $9,342,000 | $23,499,000 |
| Accounts Receivable | $73,977,000 | $63,009,000 | $52,093,000 | $33,584,000 |
| Cash Cash Equivalents And Short Term Investments | $864,153,000 | $820,376,000 | $442,626,000 | $402,472,000 |
| Cash And Cash Equivalents | $467,709,000 | $455,731,000 | $442,626,000 | $402,472,000 |
| Allowance For Doubtful Accounts Receivable | - | - | $-535,000 | $0 |
| Gross Accounts Receivable | - | - | $52,628,000 | $33,584,000 |
| Non Current Prepaid Assets | - | - | - | $7,205,000 |
| Investmentin Financial Assets | - | - | - | $137,000 |
| Goodwill And Other Intangible Assets | - | - | - | $410,000 |
| Other Receivables | - | - | - | $18,975,000 |
| Cash Financial | - | - | - | $332,539,000 |
| Debt | ||||
| Total Debt | $436,687,000 | $432,722,000 | $85,010,000 | $81,449,000 |
| Long Term Debt And Capital Lease Obligation | $434,681,000 | $431,175,000 | $83,622,000 | $79,567,000 |
| Long Term Debt | $393,125,000 | $391,013,000 | $48,011,000 | $47,807,000 |
| Current Debt And Capital Lease Obligation | $2,006,000 | $1,547,000 | $1,388,000 | $1,882,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $686,236,000 | $648,790,000 | $228,158,000 | $187,859,000 |
| Total Non Current Liabilities Net Minority Interest | $439,539,000 | $436,609,000 | $89,137,000 | $87,024,000 |
| Non Current Deferred Liabilities | $4,858,000 | $5,434,000 | $5,515,000 | $5,242,000 |
| Current Liabilities | $246,697,000 | $212,181,000 | $139,021,000 | $100,835,000 |
| Current Deferred Liabilities | $583,000 | $0 | $0 | $7,756,000 |
| Payables And Accrued Expenses | $227,566,000 | $197,532,000 | $126,035,000 | $82,047,000 |
| Interest Payable | $4,193,000 | $4,205,000 | $10,000 | - |
| Payables | $24,364,000 | $25,100,000 | $17,798,000 | $15,572,000 |
| Accounts Payable | $24,364,000 | $25,100,000 | $17,798,000 | $14,450,000 |
| Total Tax Payable | - | - | $1,807,000 | $1,122,000 |
| Equity | ||||
| Common Stock Equity | $381,033,000 | $360,716,000 | $368,843,000 | $338,903,000 |
| Total Equity Gross Minority Interest | $381,033,000 | $360,716,000 | $368,843,000 | $338,903,000 |
| Stockholders Equity | $381,033,000 | $360,716,000 | $368,843,000 | $338,903,000 |
| Other Equity Interest | $1,000 | $1,000 | $1,000 | $1,000 |
| Gains Losses Not Affecting Retained Earnings | $-28,084,000 | $-33,763,000 | $-36,261,000 | $-54,673,000 |
| Other Equity Adjustments | $-28,084,000 | $-33,763,000 | $-36,261,000 | $-54,673,000 |
| Retained Earnings | $-831,275,000 | $-795,761,000 | $-744,674,000 | $-689,387,000 |
| Other | ||||
| Ordinary Shares Number | $50,689,271 | $50,064,860 | $49,725,649 | $48,088,346 |
| Share Issued | $50,689,271 | $50,064,860 | $49,725,649 | $48,088,346 |
| Tangible Book Value | $381,033,000 | $360,716,000 | $368,843,000 | $338,903,000 |
| Invested Capital | $774,158,000 | $751,729,000 | $416,854,000 | $386,710,000 |
| Working Capital | $750,045,000 | $717,683,000 | $389,799,000 | $373,142,000 |
| Capital Lease Obligations | $43,562,000 | $41,709,000 | $36,999,000 | $33,642,000 |
| Total Capitalization | $774,158,000 | $751,729,000 | $416,854,000 | $386,710,000 |
| Additional Paid In Capital | $1,240,255,000 | $1,190,104,000 | $1,149,643,000 | $1,082,833,000 |
| Capital Stock | $136,000 | $135,000 | $134,000 | $129,000 |
| Common Stock | $136,000 | $135,000 | $134,000 | $129,000 |
| Non Current Deferred Revenue | $4,858,000 | $5,434,000 | $5,515,000 | $5,242,000 |
| Long Term Capital Lease Obligation | $41,556,000 | $40,162,000 | $35,611,000 | $31,760,000 |
| Current Deferred Revenue | $583,000 | $0 | $0 | $7,756,000 |
| Current Capital Lease Obligation | $2,006,000 | $1,547,000 | $1,388,000 | $1,882,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $16,542,000 | $13,102,000 | $11,598,000 | $9,150,000 |
| Current Accrued Expenses | $203,202,000 | $172,432,000 | $108,237,000 | $66,475,000 |
| Net PPE | $50,245,000 | $47,735,000 | $42,735,000 | $38,777,000 |
| Accumulated Depreciation | $-60,803,000 | $-55,321,000 | $-52,307,000 | $-45,668,000 |
| Gross PPE | $111,048,000 | $103,056,000 | $95,042,000 | $84,445,000 |
| Leases | $22,420,000 | $21,020,000 | $20,020,000 | $19,095,000 |
| Construction In Progress | $1,134,000 | $477,000 | $46,000 | $431,000 |
| Other Properties | $83,637,000 | $78,025,000 | $73,054,000 | $63,209,000 |
| Machinery Furniture Equipment | $3,857,000 | $3,534,000 | $1,922,000 | $1,710,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $396,444,000 | $364,645,000 | $0 | - |
| Non Current Accrued Expenses | - | - | $978,000 | $2,215,000 |
| Foreign Currency Translation Adjustments | - | - | - | $-3,097,000 |
| Long Term Provisions | - | - | - | $114,000 |
| Current Provisions | - | - | - | $51,000 |
| Investments And Advances | - | - | - | $137,000 |
| Available For Sale Securities | - | - | - | $137,000 |
| Other Investments | - | - | - | - |
Fetched: 2026-06-14
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-15,052,000 | $20,888,000 | $-2,485,000 | $-51,412,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-10,712,000 | $26,061,000 | $2,940,000 | $-49,209,000 |
| Cash Flow From Continuing Operating Activities | $-10,712,000 | $26,061,000 | $2,940,000 | $-49,209,000 |
| Operating Gains Losses | $-6,385,000 | $4,452,000 | $13,827,000 | $-12,796,000 |
| Investing Activities | ||||
| Capital Expenditure | $-4,340,000 | $-5,173,000 | $-5,425,000 | $-2,203,000 |
| Investing Cash Flow | $-16,340,000 | $-355,129,000 | $-5,425,000 | $-2,197,000 |
| Cash Flow From Continuing Investing Activities | $-16,340,000 | $-355,129,000 | $-5,425,000 | $-2,197,000 |
| Net Other Investing Changes | - | - | - | $2,886,326 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $0 | $0 | $139,515,000 |
| Financing Cash Flow | $12,371,000 | $343,881,000 | $34,346,000 | $145,442,000 |
| Cash Flow From Continuing Financing Activities | $12,371,000 | $343,881,000 | $34,346,000 | $145,442,000 |
| Net Common Stock Issuance | $0 | $0 | $0 | $139,515,000 |
| Common Stock Issuance | $0 | $0 | $0 | $139,515,000 |
| Net Other Financing Charges | - | $-15,419,000 | - | $-3,769,000 |
| Cash Dividends Paid | - | - | - | $0 |
| Other | ||||
| Repayment Of Debt | $0 | $-50,000,000 | $0 | $-50,000,000 |
| Issuance Of Debt | $0 | $402,500,000 | $0 | $50,000,000 |
| Interest Paid Supplemental Data | $10,062,000 | $9,235,000 | - | $4,482,000 |
| Income Tax Paid Supplemental Data | $4,643,000 | $510,000 | $977,000 | $765,000 |
| End Cash Position | $467,709,000 | $455,731,000 | $442,626,000 | $402,472,000 |
| Beginning Cash Position | $455,731,000 | $442,626,000 | $402,472,000 | $321,082,000 |
| Effect Of Exchange Rate Changes | $26,659,000 | $-1,708,000 | $8,293,000 | $-12,646,000 |
| Changes In Cash | $-14,681,000 | $14,813,000 | $31,861,000 | $94,036,000 |
| Proceeds From Stock Option Exercised | $12,371,000 | $6,800,000 | $34,346,000 | $9,696,000 |
| Net Issuance Payments Of Debt | $0 | $352,500,000 | $0 | $0 |
| Net Long Term Debt Issuance | $0 | $352,500,000 | $0 | $0 |
| Long Term Debt Payments | $0 | $-50,000,000 | $0 | $-50,000,000 |
| Long Term Debt Issuance | $0 | $402,500,000 | $0 | $50,000,000 |
| Net Investment Purchase And Sale | $-12,000,000 | $-350,000,000 | $0 | $0 |
| Sale Of Investment | $18,000,000 | $0 | $0 | - |
| Purchase Of Investment | $-30,000,000 | $-350,000,000 | $0 | $0 |
| Net PPE Purchase And Sale | $-4,340,000 | $-5,129,000 | $-5,425,000 | $-2,197,000 |
| Sale Of PPE | $0 | $44,000 | $0 | $6,000 |
| Purchase Of PPE | $-4,340,000 | $-5,173,000 | $-5,425,000 | $-2,203,000 |
| Change In Working Capital | $-9,300,000 | $48,952,000 | $11,625,000 | $-24,165,000 |
| Change In Other Working Capital | $-387,000 | $-1,000 | $-8,013,000 | $-25,504,000 |
| Change In Other Current Liabilities | $-2,093,000 | $-1,648,000 | $-3,579,000 | $356,000 |
| Change In Other Current Assets | $-6,177,000 | $-4,225,000 | $-9,169,000 | $-4,729,000 |
| Change In Payables And Accrued Expense | $13,433,000 | $78,774,000 | $41,713,000 | $46,670,000 |
| Change In Accrued Expense | $15,889,000 | $71,502,000 | $39,088,000 | $41,757,000 |
| Change In Payable | $-2,456,000 | $7,272,000 | $2,625,000 | $4,913,000 |
| Change In Account Payable | $-2,456,000 | $7,272,000 | $2,625,000 | $4,913,000 |
| Change In Prepaid Assets | $-6,740,000 | $-11,600,000 | $8,544,000 | $-14,694,000 |
| Change In Receivables | $-7,336,000 | $-12,348,000 | $-17,871,000 | $-26,264,000 |
| Changes In Account Receivables | $-7,336,000 | $-12,348,000 | $-17,871,000 | $-26,264,000 |
| Other Non Cash Items | $4,461,000 | $3,750,000 | $2,059,000 | $2,072,000 |
| Stock Based Compensation | $37,698,000 | $34,190,000 | $32,469,000 | $32,888,000 |
| Unrealized Gain Loss On Investment Securities | $-19,728,000 | $-14,577,000 | $0 | $0 |
| Deferred Tax | $14,790,000 | $-3,823,000 | $-5,843,000 | $-3,534,993 |
| Deferred Income Tax | $14,790,000 | $-3,823,000 | $-5,843,000 | $-3,534,993 |
| Depreciation Amortization Depletion | $3,266,000 | $4,204,000 | $4,090,000 | $5,335,000 |
| Depreciation And Amortization | $3,266,000 | $4,204,000 | $4,090,000 | $5,335,000 |
| Depreciation | $3,266,000 | $4,204,000 | $4,090,000 | $5,335,000 |
| Net Foreign Currency Exchange Gain Loss | $-6,385,000 | $599,000 | $13,827,000 | $-14,482,000 |
| Net Income From Continuing Operations | $-35,514,000 | $-51,087,000 | $-55,287,000 | $-52,543,000 |
| Interest Paid Cff | - | - | - | $-4,384,553 |
| Net Intangibles Purchase And Sale | - | - | - | $-496,182 |
| Purchase Of Intangibles | - | - | - | $-496,182 |
| Taxes Refund Paid | - | - | - | $-747,903 |
| Provisionand Write Offof Assets | - | - | - | - |
| Asset Impairment Charge | - | - | - | - |
| Amortization Cash Flow | - | - | - | - |
| Amortization Of Intangibles | - | - | - | - |
| Gain Loss On Sale Of PPE | - | - | - | - |
Fetched: 2026-06-14